Testing MT027 for advanced belly-lining cancers
Part of Cancer clinical trials.
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your cancer must have spread to the lining of your belly (peritoneal cavity) and be confirmed by a biopsy or scan.
- You must have tried at least 2 standard treatments and they didn't work, or no standard treatment is available for your cancer.
- A sample of your tumor or belly fluid must test positive for a marker called B7-H3.
- You should be in fairly good health, able to walk and take care of yourself (ECOG score 0-2), with an expected survival of at least 3 months.
- You need to have decent blood counts, liver and kidney function, and be willing to use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy, MT027, for people with advanced peritoneal tumors that have stopped responding to standard treatments. The goal is to see if MT027 can shrink tumors when injected directly into the abdomen.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This trial tests a new treatment called TH027 for people with certain advanced solid tumors (osteosarcoma, neuroblastoma, gastric cancer, or lung cancer) that have not responded to standard therapies. TH027 targets a protein called CD276 on cancer cells, which may help your immune system fight the tumor.
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
This trial tests a new treatment called KT032, a type of CAR-T cell therapy, for people with advanced solid tumors (like ovarian cancer, mesothelioma, or colon cancer) that have spread to the belly lining. The treatment is given as an injection and is designed to target a protein called mesothelin on cancer cells. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Hear when a new B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.